SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Strategies & Market TrendsSpeculating in Takeover Targets


Previous 10 Next 10 
To: richardred who wrote (3045)4/19/2012 12:19:48 AM
From: richardred
   of 7071
 
Stay Out of an Avon Bidding War
fool.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: richardred who wrote (2934)4/19/2012 10:40:37 AM
From: richardred
   of 7071
 
Glaxo’s $2.6 Billion Cash Offer Rejected by Human Genome
bloomberg.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: richardred4/19/2012 12:14:44 PM
   of 7071
 
Looks to me M&A activity is starting to pick up.



Hedge Fund Assets Jump to Record Level: Report CNBC – 2 hours 22 minutes ago









Hedge fund assets jumped to record levels in the first quarter of this year, when funds had their best first quarter in five years, according to the latest HFR Global Hedge Fund Industry Report, released on Thursday by Chicago-based research firm Hedge Fund Research.



Total investor capital allocated to hedge funds in the first quarter exceeded $16 billion, HFR said in a statement.

Combined with strong performance for hedge funds in the first quarter, when stock and credit markets gained strongly, total capital invested in the global hedge fund industry increased to $2.13 trillion, exceeding the previous record of $2.04 trillion set in mid-2011, HFR said.

Among investment strategies, those most favored by investors were fixed income-based Relative Value Arbitrage and Macro, which received "an overwhelming majority of the new investor capital for the quarter," HFR's statement said.

It said that in the first quarter, investors allocated $12.4 billion in net new capital to Relative Value Arbitrage and $7.8 billion to Macro and redeemed $2.9 billion from Equity Hedge and $940 million from Event Driven strategies.

Relative Value Arbitrage is an investment strategy which seeks to take advantage of price differentials between related financial instruments by buying and selling different securities simultaneously. Macro is a strategy based on macroeconomic trends. Equity Hedge involves taking long and short positions in separate stocks simultaneously. Event Driven investing is driven by specific events related to companies or countries.



In the first quarter, investors preference for the industry's most established managers continued to be pronounced, according to HFR. Firms with more than $5 billion in assets under management were allocated $18.3 billion in new capital in the quarter, while funds managing less than $5 billion saw a combined net outflow of nearly $2 billion over the same period.

"The record level of assets and the shifting distribution of these are indicative of powerful trends shaping the hedge fund industry in 2012," Kenneth J. Heinz, President of HFR, said in a statement.

"Sophisticated institutional investors are increasingly allocating to hedge funds as a powerful strategic portfolio complement to existing traditional holdings, utilizing transparency to balance equity market beta, access uncorrelated returns and enhance their ability to exceed target return requirements," Heinz added.

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


To: richardred who wrote (3047)4/19/2012 1:31:11 PM
From: richardred
   of 7071
 
Snip>Coty and Avon had discussed McCoy running a combined company, and Becht said in an April 2 interview that it “would not be helpful” for Avon to hire a new CEO in light of the bid.

bloomberg.com

Share RecommendKeepReplyMark as Last Read


To: richardred who wrote (3007)4/20/2012 12:04:03 AM
From: richardred
   of 7071
 
Should still leave CAG room for additions from their failed Ralcorp buget.

ConAgra to Acquire Sandwich Maker

ConAgra Foods Inc. (NYSE:CAG - News) has been significantly expanding its business portfolio over time, focusing on branded and value-added opportunities. Acquisition of a number of private labels paved way for such expansion; the latest on its list is the nation’s second largest frozen breakfast sandwich producer, Odom's Tennessee Pride.

Earlier this week, ConAgra announced its plan to acquire Odom's Tennessee Pride. The later registers annual revenue of over $190 million, working with a team of around 750 employees. The company will be acquiring Odom’s facilities in Little Rock, AR and Dickson, TN along with its headquarters in Madison, TN.

In spite of macro-economic threats, ConAgra has been significantly expanding its business – a successful reflection of which was the company’s recent third-quarter results. Further ahead, management hopes to see growth opportunities with recent signs of modest job recovery and recession in gasoline prices.

The recent acquisition is expected to support and carry forward such growth plans. ConAgra’s CEO Gary Rodkin, was quite optimistic on the acquisition, as he hopes that this stride will allow the company to strengthen its portfolio across growing breakfast category. The financial terms of the acquisition have not yet been disclosed.

The acquisition, backed by the optimism of product line expansion and diversification, is envisaged to offer stiff competition to many of the industry players including, HJ Heinz Co. (NYSE:HNZ - News) and Kraft Foods Inc. (NYSE:KFT - News). Moreover, ConAgra expects the rate of input cost inflation to moderate in the upcoming quarters and envisages improved plant efficiencies.

We hold a Neutral recommendation on ConAgra over the long term. However, ConAgra retains a Zacks #4 Rank, implying a short-term (1-3 months) Sell rating.
finance.yahoo.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: richardred4/20/2012 10:18:34 AM
   of 7071
 
SNDK- I think there's an bit of a overreaction on the bad news. Have it on my radar for a possible addition. IMO the weakness represents a good opportunity if conditions present themselves. Looking for a bottom.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: richardred who wrote (3051)4/20/2012 11:50:21 AM
From: richardred
   of 7071
 
LNCE-Sold half my position today for a nice long term gain. Earnings are out soon and I want to lock in some unrealized gains in case of a unfavorable surprise.

Share RecommendKeepReplyMark as Last Read


To: richardred who wrote (2895)4/20/2012 1:51:31 PM
From: richardred
   of 7071
 
Here's one maybe!


GE's Immelt says may do some smaller bolt on acquisitions

theflyonthewall.com

Share RecommendKeepReplyMark as Last Read


From: richardred4/23/2012 9:33:07 AM
   of 7071
 
Ardea soars on takeover dealDeal Would Add Late-Stage Compound

Ardea Biosciences agreed to be acquired by AstraZeneca for $32 a share. The company's most advanced product compound, Lesinurad, is currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout. RDEA is up 51 percent in the premarket.

ConocoPhillips reported first-quarter earnings of $2.02 a share. Analysts had expected $2.08 average analyst forecast, and COP is down more than 2 percent before the bell.

Kellogg Lowers Guidance

Kellogg expects full-year earnings of $3.18 to $3.30 a share, down from an earlier forecast of $3.44 to $3.51. Management blamed weak first-quarter results, slowness in Europe and stagnation in certain U.S. categories. K is down 6 percent in premarket trade on my tradeMONSTER platform.

Amylin Seeks a Buyer

Amylin Pharmaceuticals has hired Credit Suisse and Goldman Sachs to help find a buyer. The company had turned down a takeover off from Bristol-Myers Squibb earlier in the year. AMLN rose 11 percent before the bell.

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


To: richardred who wrote (3046)4/23/2012 9:36:17 AM
From: richardred
   of 7071
 
Nestle to Finance Pfizer Baby-Food Unit Purchase With Debt
Nestle SA, (NESN) the world’s biggest food maker, plans to fund its $11.9 billion acquisition of Pfizer Inc. (PFE)’s baby-food unit with debt.

bloomberg.com

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10